ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada2026
C-reactive protein-albumin-lymphocyte index predicts biochemical recurrence in prostate cancer.
Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Prognostic value of the CALLY index for functional outcomes in acute ischemic stroke: a systematic review and exploratory quantitative synthesis.Frontiers in neurology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSystemic inflammation and nutritional status influence prostate cancer outcomes. The C-reactive protein-albumin-lymphocyte (CALLY) index integrates these parameters, but its ability to predict biochemical recurrence (BCR) is not well-established.
methodsIn a single-center, retrospective cohort of 600 patients (2018-2022), the pretreatment CALLY index was calculated as (albumin [g/dL] × lymphocytes [cells/μL])/(CRP [mg/dL] × 10
resultsOver a median followup of 28.4 months, 26.8% developed BCR. The optimal CALLY threshold was 1524.2, demonstrating modest discriminative ability (area under the curve [AUC] 0.684, 95% confidence interval [CI] 0.624-0.744; sensitivity 72.4%, specificity 64.8%). Low CALLY was associated with higher 36-month BCR rates (31.4% vs. 21.6%; log-rank p=0.042). In multivariable analysis, CALLY independently predicted BCR both as a continuous measure (per 100-unit increase: hazard ratio [HR] 0.882, 95% CI 0.778-0.998, p=0.048) and dichotomized at the median (HR 0.798, 95% CI 0.642-0.992, p=0.042), alongside baseline PSA and Gleason ≥4+4. Adding CALLY modestly improved discrimination of CAPRA (C-index 0.71-0.74) and Memorial Sloan Kettering Cancer Center (MSKCC) (0.73-0.76) models, with NRI 0.246 (p=0.006) and net clinical benefit on DCA across 10-40% thresholds. Effects were most pronounced in high-risk and surgically treated patients.
conclusionsThe pre-treatment CALLY index represents a readily available biomarker that independently predicts BCR and may complement established risk-stratification tools in prostate cancer, although model performance was modest. External validation in prospective cohorts with longer followup is necessary before clinical implementation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.